Double-stranded miRNAs, pharmaceutical compositions containing them, anti-aging products and their uses

By combining chemically modified double-stranded miRNAs with vectors, the problems of stability and low cellular uptake of miRNA delivery systems have been solved, achieving effective anti-aging treatments and significant therapeutic effects on a variety of diseases.

CN123063401APending Publication Date: 2026-11-10YUANSHENG BIOTECH (TSING DAO) CO LTD
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202611356279.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-10-28
Publication Date
2026-11-10

AI Technical Summary

Technical Problem

Existing miRNA delivery systems suffer from problems such as poor stability, low cellular uptake, strong immune response, high production costs, and carcinogenic risks, making them difficult to use effectively for anti-aging treatments.

Method used

Chemically modified double-stranded miRNAs, including 2'-substituted nucleotides and modified nucleotide bonds, 2'-O-methylation at specific sites, and LNA modification, are combined with pharmaceutically acceptable carriers to form stable liposome nanoparticles.

Benefits of technology

It achieves improved stability and cellular uptake efficiency of miRNA in vivo, exhibits anti-aging capabilities at the whole animal level, and significantly treats photoaging of skin cells and various diseases, such as Alzheimer's disease, articular cartilage damage, and diabetes.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure FT_1
    Figure FT_1
  • Figure FT_2
    Figure FT_2
  • Figure FT_3
    Figure FT_3
Patent Text Reader

Abstract

This invention discloses a double-stranded miRNA, a pharmaceutical composition containing the same, an anti-aging product, and its uses. The double-stranded miRNA comprises a chemically modified sense strand as shown in SEQ ID NO:1, and a chemically modified antisense strand as shown in SEQ ID NO:2; wherein the chemical modification of the sense and antisense strands each comprises a 2'-substituted nucleotide and a modified nucleotide bond; the chemically modified nucleotide bond is located at least one or more positions in positions 1-3 and 20-23 of the sequences shown in SEQ ID NO:1 and / or SEQ ID NO:2. This double-stranded miRNA exhibits good stability and significant therapeutic effects on photoaging of skin cells, Alzheimer's disease, articular cartilage damage, diabetes, non-alcoholic fatty liver disease, androgenetic alopecia, cirrhosis, and chronic nephritis. In short, it balances the efficacy and stability of the product and has promising application prospects.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This application belongs to the field of biomedicine, specifically relating to a double-stranded miRNA, a pharmaceutical composition containing it, an anti-aging product, and its uses. Background Technology

[0002] Aging is a process that all living things must face. Finding ways to unlock the biological mechanisms of aging and to delay or reverse it has always been a hot topic in the scientific community, and it also has significant social implications and enormous commercial value. Aging is divided into several levels: individual aging, organ aging, and cellular aging. The aging of individuals and organs ultimately manifests in cellular aging.

[0003] MicroRNAs (miRNAs) are non-coding single-stranded RNA molecules of 18-25 nucleotides in length encoded by endogenous genes. miRNAs are involved in a variety of biological processes. One way is that miRNAs bind complementaryly to target genes, ultimately cleaving the target mRNA. Another way is that they bind incompletely complementaryly to target genes, inhibiting the translation of the target gene.

[0004] Previous research by our team has suggested that miR302b can break the cell cycle arrest of senescent cells at the cellular level, prompting senescent cells to return to the cell cycle and regain proliferative capacity, while maintaining their original functions without transdifferentiation or reprogramming—a process known as "reverse aging." However, in terms of application, various methods have different advantages and disadvantages. Direct administration of miR302b is difficult to penetrate the cell membrane due to the lack of a delivery system, resulting in low uptake rates; unmodified small nucleic acids have poor stability and are easily degraded due to the large number of nucleases present in cells, preventing them from reaching effective concentrations; the lack of necessary transport systems makes effective gene silencing difficult; in addition, natural small nucleic acids may trigger immune responses, be recognized as pathogen molecules, and activate interferon and other cytokines, affecting normal cell function and interfering with the gene silencing effect of small nucleic acids; exosomes carrying miR302b have large batch-to-batch variations, making drug development difficult; AAV virus carrying miR302b has difficulties in ensuring uniform dosage, non-specific expression, easy immune responses, high production costs, and potential carcinogenic risks. Therefore, the miRNA mimic approach is particularly necessary. In addition, siRNA mainly functions by forming an RNA-induced silencing complex (RISC) with Ago2 in the cell; miRNA functions by binding to Ago1-4 proteins of the Ago family to form RISC. Different miRNA modifications may lead to different binding forces, which makes the miRNA mimic process more complex.

[0005] Chemical modifications of miRNAs can significantly affect their stability, specificity, cellular uptake efficiency, and biological activity. Different types of modifications have different effects in these aspects; modifications at a single site and combined modifications at multiple sites may have different effects; and specific patterns of modification may enhance or weaken the function of miRNAs. Summary of the Invention

[0006] Therefore, it is necessary to provide a double-stranded miRNA, a pharmaceutical composition containing it, an anti-aging product, and its uses.

[0007] In a first aspect, this application provides a double-stranded miRNA comprising a sense strand with a chemically modified sequence as shown in SEQ ID NO:1, and an antisense strand with a chemically modified sequence as shown in SEQ ID NO:2;

[0008] The chemical modifications of the sense strand and the antisense strand each comprise a 2'-substituted nucleotide and a modified nucleotide bond; the chemically modified nucleotide bond is located at least one or more of positions 1-3 and 20-23 of the sequences shown in SEQ ID NO: 1 and / or SEQ ID NO: 2.

[0009] In some embodiments, the 2'-substituted nucleotide is selected from one or more of 2'-fluorine substitution modification and 2'-O-methylation.

[0010] In some embodiments, the 2'-O-methylation is located at one or more of positions 1-23 of the sequences shown in SEQ ID NO: 1 and / or SEQ ID NO: 2.

[0011] In some embodiments, the 2'-O-methylation is located at one or more of the first and fourth to 23rd positions of the sequence shown in SEQ ID NO: 1 and / or SEQ ID NO: 2.

[0012] In some embodiments, the 2'-O-methylation is located at one or more of the first, fourth-12th, and fourth-23rd positions of the sequence shown in SEQ ID NO: 1 and / or SEQ ID NO: 2.

[0013] In some embodiments, the 2'-O-methylation is located at one or more of the following positions: position 1, positions 9-12, positions 14-16, and positions 20-23 of the sequence shown in SEQ ID NO: 1 and / or SEQ ID NO: 2.

[0014] In some embodiments, the 2'-O-methylation is located at positions 1-2 and 22-23, and at positions 3-21, of the sequences shown in SEQ ID NO: 1 and / or SEQ ID NO: 2.

[0015] In some embodiments, the modified nucleotide bond is selected from the group consisting of thiophosphate, dithiophosphate, phosphate triester, aminoalkyl phosphate triester, phosphonic acid alkyl ester, phosphonite, aminophosphate, thiocarbonyl aminophosphate, thiocarbonyl alkyl phosphonate, thiocarbonyl alkyl phosphate triester, selenophosphate, boron phosphate, morpholino, siloxane, sulfide, sulfoxide, sulfone, formyl, thioformyl, methyleneformyl, nucleoacetyl, olefin-containing backbone, aminosulfonate, methyleneimino, methylenehydrazine, sulfonate, sulfonamide, and amide.

[0016] In some embodiments, the modified nucleotide bond is a thiophosphate.

[0017] In some embodiments, the 2'-fluorine substitution modification occurs in one or more of the following groups: nucleotides containing cytosine, nucleotides containing adenine, and nucleotides containing uracil.

[0018] In some embodiments, the 2'-fluorine substitution modification is located at least in the spacer positions of positions 3-21 of the sequence shown in SEQ ID NO: 1 and / or SEQ ID NO: 2; for example, at least in one or more of positions 3, 5, 7, 9, 11, 13, 15, 17, 19, and 21 of the sequence shown in SEQ ID NO: 1 and / or SEQ ID NO: 2, or at least in one or more of positions 4, 6, 8, 10, 12, 14, 18, and 20 of the sequence shown in SEQ ID NO: 1 and / or SEQ ID NO: 2.

[0019] In some implementations, the justice chain and / or the antisense chain further include LNA modifications.

[0020] In some implementations, the LNA modification is located in one or more of the first to eighth positions of the sequence shown in SEQ ID NO: 2.

[0021] In some embodiments, the LNA modification is located in the spacer position between positions 1-8 of the sequence shown in SEQ ID NO: 2.

[0022] In some implementations, the LNA modification excludes other modifications besides the LNA modification at the site.

[0023] In some implementations, all sites other than those with LNA modification are 2'-O-methylated.

[0024] In some implementations, the sense strand and / or the antisense strand further comprise DNA modifications.

[0025] In some embodiments, the DNA modification is replaced with thymine.

[0026] In some embodiments, at least one uracil site in the positive chain has a DNA modification.

[0027] In some embodiments, at least one uracil site in the antisense strand has a DNA modification.

[0028] In some implementations, one or more of the 5th, 8th, 13th, 17th and 18th positions of the sequence shown in SEQ ID NO: 1 are replaced with thymine.

[0029] In some implementations, positions 5, 13, 17, and 18 of the sequence shown in SEQ ID NO: 1 are replaced with thymine.

[0030] In some implementations, positions 5, 8, 17, and 18 of the sequence shown in SEQ ID NO: 1 are replaced with thymine.

[0031] In some implementations, the 8th position of the sequence shown in SEQ ID NO: 1 is replaced with thymine.

[0032] In some implementations, all uracil in the sequence shown in SEQ ID NO: 1 are replaced with thymine.

[0033] In some embodiments, at least one or more of the 5th, 8th, 13th, 17th and 18th positions of the sequence shown in SEQ ID NO: 2 are replaced with thymine.

[0034] In some implementations, one or more of the 5th, 8th, 13th, 17th and 18th positions of the sequence shown in SEQ ID NO: 2 are replaced with thymine.

[0035] In some implementations, the fifth position of the sequence shown in SEQ ID NO: 2 is replaced with thymine.

[0036] In some implementations, all uracil in the sequence shown in SEQ ID NO: 2 are replaced with thymine.

[0037] In some implementations, the justice chain and / or the antisense chain further include end modifications.

[0038] In some embodiments, the end modification is a 3' end with a 5' NN 3' structure protrusion, wherein each occurrence of N is independently selected from the group consisting of adenine (A), thymine (T), cytosine (C), guanine (G) and uracil (U).

[0039] In some embodiments, the protruding end is chemically modified.

[0040] In some embodiments, the protruding end is selected from the group consisting of 5' Nm Nm 3', 5' sN sN 3', 5' Nm sN 3', 5' sN Nm 3', 5' sNm Nms 3', 5' sNm Nm 3', 5' Nm sNm 3', 5' sNm sN3' and 5' sN sNm 3'.

[0041] In some implementations, the NN is selected from the group consisting of UG, TT, AC, and AA.

[0042] In some embodiments, the protruding end is selected from the group consisting of 5' sTm sTm 3', 5' sUm sGm 3', 5' sAmsCm 3' and 5' sAm sAm 3'.

[0043] In some embodiments, the sense chain and / or the antisense chain further comprises at least one terminal group.

[0044] In some embodiments, the terminal group is a 3' terminal group.

[0045] In some embodiments, the 3' terminal group is selected from the group consisting of cholesterol, bile acids, fatty acids, polyethylene glycol, antibodies, polymers, and N-acetylgalactosamine (GalNAC).

[0046] A second aspect of this application provides a pharmaceutical composition comprising a double-stranded miRNA as described in the first aspect, and a pharmaceutically acceptable carrier.

[0047] A third aspect of this application provides an anti-aging product comprising the double-stranded miRNA as described in the first aspect.

[0048] The fourth aspect of this application provides the use of the double-stranded miRNA as described in the first aspect in the preparation of anti-aging products, medicaments for treating Alzheimer's disease, medicaments for treating articular cartilage damage, medicaments for treating diabetes, medicaments for treating non-alcoholic fatty liver disease, medicaments for treating cirrhosis, medicaments for treating androgenetic alopecia, or medicaments for treating chronic nephritis.

[0049] In some embodiments, the anti-aging product, the drug for treating Alzheimer's disease, the drug for treating articular cartilage damage, the drug for treating diabetes, the drug for treating non-alcoholic fatty liver disease, the drug for treating cirrhosis, the drug for treating androgenetic alopecia, or the drug for treating chronic nephritis may be administered via a method selected from the group consisting of intravenous, intramuscular, intra-articular, intrathecal, intracapsular, intra-abdominal, intraorbital, intracardiac, intradermal, intraperitoneal, tracheal, subcutaneous, subepidermal, intra-articular, subcapsular, subarachnoid, spinal, and intrasternal injection and infusion.

[0050] In a fifth aspect of this application, liposome nanoparticles comprising double-stranded miRNA as described in the first aspect are provided.

[0051] The double-stranded miRNA prepared in one embodiment of this application has at least the following effects:

[0052] It exhibits good stability, remaining intact in vivo for several hours; it possesses anti-aging capabilities at the whole-animal level; and it shows significant therapeutic effects on various diseases, including photoaging of skin cells, Alzheimer's disease, articular cartilage damage, diabetes, non-alcoholic fatty liver disease, androgenetic alopecia, cirrhosis, and chronic nephritis. In short, it balances efficacy and stability, demonstrating promising application prospects. Attached Figure Description

[0053] To more clearly illustrate the technical solutions in the embodiments and examples of this application, and to more completely understand this application and its beneficial effects, the drawings used in the description of the embodiments or examples will be briefly introduced below. Obviously, the drawings described below are merely some embodiments of this application. Those skilled in the art can obtain other drawings based on these drawings without creative effort. It should also be noted that the drawings are all drawn in a simplified form and are only used to conveniently and clearly assist in illustrating this application. The various dimensions of each component shown in the drawings are arbitrarily shown; they may be precise or not drawn to scale. For example, to make the illustration clearer, the dimensions of some components are appropriately exaggerated in the drawings. Unless otherwise specified, the components in the drawings are not drawn to scale. The drawings of this application do not limit each dimension of each component.

[0054] Figure 1This is the basic preparation process for small nucleic acid single strands in one embodiment of this application.

[0055] Figure 2 This is a schematic diagram illustrating the determination of the expected binding site of miR-302b in one embodiment of this application.

[0056] Figure 3 This is an embodiment of the method by which cholesterol and nucleic acid chains are linked. Detailed Implementation

[0057] To facilitate understanding of this application, the invention will now be described more fully with reference to the accompanying drawings. Preferred embodiments of the invention are shown in the drawings. However, the invention can be implemented in many different forms and is not limited to the embodiments described herein. Rather, these embodiments are provided to provide a thorough and complete understanding of the disclosure of this invention.

[0058] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. The terminology used herein in the description of the invention is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. The term "and / or" as used herein includes any and all combinations of one or more of the associated listed items.

[0059] In this application, unless otherwise specified, "one or more" means any one of the listed items or any combination of the listed items. Similarly, "one or more" and other instances that otherwise indicate "one or more" shall be understood in the same way unless otherwise specified.

[0060] The terms “combinations thereof,” “any combination thereof,” and “any combination thereof” as used in this application include all suitable combinations of any two or more of the listed items.

[0061] In this application, the word "suitable" in "suitable combination", "suitable method", "any suitable method" etc., shall be defined as being able to implement the technical solution of this application, solve the technical problem of this application, and achieve the expected technical effect of this application.

[0062] In this application, terms such as "further," "even more," "particularly," "for example," "like," "example," and "exemplary" are used for descriptive purposes to indicate that different technical solutions preceding and following each other are related in terms of their coverage, but should not be construed as limiting the preceding technical solution or restricting the scope of protection of this application. In this application, unless otherwise specified, A (e.g., B) indicates that B is a non-limiting example of A, and it can be understood that A is not limited to B.

[0063] In this application, "optionally," "optionally," and "optional" mean that something is optional, that is, it refers to either "with" or "without" a parallel solution. If multiple "options" appear in a technical solution, unless otherwise specified and there are no contradictions or mutual constraints, each "option" is independent. Unless otherwise specified, the descriptions such as "optionally include" and "optionally contain" in this application, taking "optionally include" as an example, mean "may include or not include."

[0064] The terms “containing,” “comprising,” and “including” as used in this application are synonyms and are inclusive or open-ended, not excluding additional, uncited members or features. Members or features include, for example, materials or components, structures, elements, instruments, etc.; non-limiting examples of members or features include actions, conditions under which actions occur, timing, states, etc.

[0065] The terms “and / or,” “or / and,” and “and / or” as used in this application encompass any one of two or more of the related listed items, as well as any and all combinations of the related listed items. “Any and all combinations” includes any two related listed items, any more related listed items, or a combination of all the related listed items. For example, “A and / or B” includes three parallel options: A, B, and “a combination of A and B.”

[0066] In this application, the technical features or solutions described in open-ended language include both closed-ended technical features or solutions consisting of the listed contents and open-ended technical features or solutions that include the listed contents.

[0067] In this application, the exemplary descriptions such as "in some implementations (or embodiments)" and "in one implementation (or embodiment)" may cover, but are not limited to, the following meanings: these solutions can be combined with other solutions in a suitable manner to form new technical solutions.

[0068] In this application, the terms "first aspect," "second aspect," "third aspect," "fourth aspect," etc., are used for descriptive purposes only and should not be construed as indicating or implying relative importance or quantity, nor should they be construed as implicitly indicating the importance or quantity of the indicated technical features. Moreover, "first," "second," "third," "fourth," etc., serve only a non-exhaustive enumeration purpose and should be understood not to constitute a closed limitation on quantity.

[0069] In this application, when numerical intervals (i.e., numerical ranges) are involved, unless otherwise specified, the distribution of selectable numerical values ​​within the numerical interval is considered continuous, and includes the two endpoints of the numerical interval (i.e., the minimum and maximum values), as well as every numerical value between these two endpoints. Unless otherwise specified, when a numerical interval refers only to integers within that numerical interval, it includes the two endpoint integers of the numerical range, as well as every integer between the two endpoints, which is equivalent to directly listing every integer. When multiple numerical ranges are provided to describe features or characteristics, these numerical ranges can be merged. In other words, unless otherwise specified, the numerical ranges disclosed herein should be understood to include any and all subranges included therein. The "numerical value" in the numerical interval can be any quantitative value, such as a number, percentage, ratio, etc. The term "numerical interval" can be broadly included to include numerical interval types such as percentage intervals, ratio intervals, and proportion intervals.

[0070] Unless otherwise specified, the term "nucleic acid" as used in this application refers to deoxyribonucleotides, ribonucleotides, or modified nucleotides and their polymers in single-stranded or double-stranded form. This term includes nucleic acids containing known nucleotide analogs or modified backbone residues or bonds, which are synthetic, naturally occurring, or non-natural, and have the same sequence as the reference nucleic acid. They have similar binding properties and are metabolized in a similar manner as the reference nucleotide.

[0071] Unless otherwise specified, the term "nucleotide" in this application includes those having both native (standard) and modified bases well known in the art. Nucleotides may be unmodified or modified in their sugar, phosphate, and / or base portions (which may also be interchangeably referred to as nucleotide analogs, modified nucleotides, non-natural nucleotides, non-standard nucleotides, etc.). (Eckstein et al., International PCT Publication No. WO 92 / 07065; Usman et al., International PCT Publication No. WO 93 / 15187;). Some non-limiting examples of base modifications that can be introduced into nucleic acid molecules include inosine, purine, pyridin-4-one, pyridin-2-one, phenyl, pseudouracil, 2,4,6-trimethoxybenzene, 3-methyluracil, dihydrouridine, naphthyl, aminophenyl, 5-alkylcytidine (e.g., 5-methylcytidine), 5-alkyluridine (e.g., nucleoside thymidine), 5-halouridine (e.g., 5-bromouridine), or 6-azpyrimidine or 6-alkylpyrimidine (e.g., 6-methyluridine and pseudouridine), propyne, etc. (Burgin et al., Biochemistry 35:14090, 1996; Uhlman & Peyman, supra). In this regard, "modified base" refers to nucleotide bases other than adenine, guanine, cytosine, and uracil, and their equivalents.

[0072] “RNA” refers to a molecule containing at least one ribonucleotide residue. “Ribonucleotide” refers to a nucleotide having a hydroxyl group at the 2' position of the αβ-D-furanose moiety. The term RNA includes double-stranded RNA, single-stranded RNA, isolated RNA such as partially purified RNA, substantially pure RNA, synthetic RNA, recombinant RNA, and the addition, deletion, substitution, and / or alteration of one or more nucleotides. The nucleotides in the RNA molecules of this invention may also include non-standard nucleotides, such as non-naturally occurring nucleotides or chemically synthesized nucleotides or deoxynucleotides. These modified RNAs may be referred to as analogs of naturally occurring RNA.

[0073] Unless otherwise specified, the term "modified nucleotide" in this application refers to a nucleotide having one or more modifications to its nucleoside, nucleotide base, pentose ring, or phosphate group. For example, modified nucleotides include ribonucleotides containing adenosine monophosphate, guanosine monophosphate, uridine monophosphate, and cytidine monophosphate, as well as deoxyadenosine monophosphate, deoxyguanosine monophosphate, deoxythymidine monophosphate, and deoxycytidine monophosphate. Modifications include those occurring naturally, caused by enzymes that modify nucleotides (e.g., methyltransferases). Modified nucleotides also include synthetic or non-naturally occurring nucleotides. Synthetic or non-natural modifications in nucleotides include 2' modifications, such as 2'-O-methyl, 2'-methoxyethoxy, 2'-fluorine, 2'-allyl, 2'-O-[2-(methylamino)-2-oxoethyl], 4'-thio, 4'-CH2-O-2'-bridging, and 4'-(CH2)2, including those containing -O-2'-bridging, 2'-LNA, and 2'-O-(methyl N-carbamate) or base analogs. The term "amino," in the context of 2'-modified nucleotides described in this disclosure, refers to 2'-NH2 or 2'-O-NH2, which may or may not be modified. Such modifying groups are described, for example, in U.S. Patent 5,672,695 to Eckstein et al. and U.S. Patent 6,248,878 to Maturic-Adamic et al.

[0074] Unless otherwise specified, the terms "microRNA" or "miRNA" in this application refer to nucleic acids that form single-stranded RNA and, when expressed in cells identical to the gene or target gene, alter (decrease or inhibit expression, regulate expression, or directly or indirectly increase expression) the expression of the gene or target gene. In one embodiment, miRNA refers to a nucleic acid that is substantially or completely identical to the target gene and forms a single-stranded miRNA. In some embodiments, miRNA may exist in the form of pre-miRNA, wherein the pre-miRNA is a double-stranded RNA. The sequence of the miRNA may correspond to the full-length target gene or its subsequence. Typically, the length of miRNA is at least about 15-50 nucleotides (e.g., each sequence of a single-stranded miRNA is 15-50 nucleotides long, and the length of a double-stranded precursor miRNA is about 15-50 base pairs). In some embodiments, miRNA is 20-30 base nucleotides long. In some embodiments, miRNA is 20-25 nucleotides long. In some implementations, the miRNA is 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 nucleotides in length.

[0075] The exemplary double-stranded miRNAs with preliminary effects prepared in this application are shown in the table below. Among them, mimic5-6, mimic10, mimic12-19, mimic22, mimic23, mimic24, mimic25, mimic26, mimic27, mimic28, mimic29, and mimic30 have particularly significant effects.

[0076] Table 1

[0077]

[0078] Table 1 (continued)

[0079]

[0080] In a first aspect of this application, a double-stranded miRNA is provided, comprising a sense strand with a chemically modified sequence as shown in SEQ ID NO:1, and an antisense strand with a chemically modified sequence as shown in SEQ ID NO:2;

[0081] The chemical modifications of the sense strand and the antisense strand each comprise a 2'-substituted nucleotide and a modified nucleotide bond; the modified nucleotide bond is located at at least one or more positions (on the nucleotide) at the 5' end and 3' end of the sequences shown in SEQ ID NO: 1 and / or SEQ ID NO: 2.

[0082] Here, "and / or" means that the modified nucleotide bond may be located at at least one or more of the 5' and 3' ends of the sequence shown in SEQ ID NO: 1, and at least one or more of the 5' and 3' ends of the sequence shown in SEQ ID NO: 2; or it may be located at least one or more of the 5' and 3' ends of the sequences shown in either SEQ ID NO: 1 or SEQ ID NO: 2. Unless otherwise specified, "and / or" in conjunction with SEQ ID NO: 1 and SEQ ID NO: 2 shall have at least the above meaning.

[0083] The 5' end may be the first 10 nucleotides (which can be used interchangeably with "first 10 positions"; the same below), the first 9 nucleotides, the first 8 nucleotides, the first 7 nucleotides, the first 6 nucleotides, the first 5 nucleotides, the first 4 nucleotides, the first 3 nucleotides, the first 2 nucleotides, or the first 1 nucleotide of the 5' end of the sequence shown in SEQ ID NO: 1 or SEQ ID NO: 2.

[0084] The 3' end may be the first 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 nucleotides of the 3' end of the sequence shown in SEQ ID NO: 1 or SEQ ID NO: 2.

[0085] Modified nucleotide bonds

[0086] In some embodiments, the modified nucleotide bond is located at both the 5' and 3' ends. In some embodiments, the modified nucleotide bond is located only at the 5' end or the 3' end.

[0087] In some embodiments, the 5' end is the first 3 nucleotides (positions 1-3 of the sequence shown in SEQ ID NO: 1 or 2), the first 2 nucleotides (positions 1-3 and 1-2 of the sequence shown in SEQ ID NO: 1 or 2), or the first 1 nucleotide (positions 1-3 and 1 of the sequence shown in SEQ ID NO: 1 or 2).

[0088] In some embodiments, the 3' end is the first 4 nucleotides (positions 20-23 of the sequence shown in SEQ ID NO: 1 or 2), the first 3 nucleotides (positions 21-23 of the sequence shown in SEQ ID NO: 1 or 2), the first 2 nucleotides (positions 22-23 of the sequence shown in SEQ ID NO: 1 or 2), or the first 1 nucleotide (position 23 of the sequence shown in SEQ ID NO: 1 or 2).

[0089] In some embodiments, the modified nucleotide bond is located at at least one or more of positions 1-3 and 20-23 of the sequences shown in SEQ ID NO: 1 and / or SEQ ID NO: 2.

[0090] In some embodiments, the modified nucleotide bond is located at least at positions 1-2 of the sequence shown in SEQ ID NO: 1. In some embodiments, the modified nucleotide bond is located only at positions 1-2 of the sequence shown in SEQ ID NO: 1.

[0091] In some embodiments, the modified nucleotide bond is located at at least one or more of positions 1-3 and one or more of positions 20-23 of the sequence shown in SEQ ID NO: 1. Exemplarily, the modified nucleotide bond is located at least or only in the sequence shown in SEQ ID NO: 1.

[0092] The first three digits, and the 22nd and 23rd digits; the first three digits, and the 21st and 23rd digits; the first three digits, and the 20th and 23rd digits; the first three digits, and the 21st and 23rd digits; the first three digits, and the 20th and 21st digits; the first three digits, and the 20th and 22nd digits; the first three digits, and the 21st and 22nd digits; the first two digits, and the 22nd and 23rd digits; the first two digits, and the 21st and 23rd digits; the first two digits, and the 20th and 21st digits; the first two digits, and the 20th and 22nd digits; the first two digits, and the 20th and 22nd digits; the first two digits, and the 20th and 22nd digits; the first two digits, and the 20th and 23rd digits. 21-22; 2-3, and 22-23; 2-3, and 21-23; 2-3, and 20-23; 2-3, and 21-23; 2-3, and 23; 2-3, and 23; 2-3, and 20-21; 2-3, and 20-22; 2-3, and 21-22; 1, and 22-23; 1, and 21-23; 1, and 20-23; 1, and 21-23; 1, and 23; 1, and 20-21; 1, and 20-22; or, 1, and 21-22.

[0093] In some embodiments, the modified nucleotide bond is selected from the group consisting of thiophosphate, dithiophosphate, phosphate triester, aminoalkyl phosphate triester, phosphonic acid alkyl ester, phosphonite, aminophosphate, thiocarbonyl aminophosphate, thiocarbonyl alkyl phosphonate, thiocarbonyl alkyl phosphate triester, selenophosphate, boron phosphate, morpholino, siloxane, sulfide, sulfoxide, sulfone, formyl, thioformyl, methyleneformyl, nucleoacetyl, olefin-containing backbone, aminosulfonate, methyleneimino, methylenehydrazine, sulfonate, sulfonamide, and amide.

[0094] In some embodiments, the modified nucleotide bond is a thiophosphate.

[0095] In this application, the modified nucleotide and the 2'-substituted nucleotide may be located at the same site in SEQ ID NO: 1 and / or SEQ ID NO: 2, or at different sites.

[0096] 2'-Substituted Nucleotides

[0097] In some embodiments, the 2'-substituted nucleotide is selected from one or more of 2'-fluorine substitution modification and 2'-O-methylation.

[0098] In some embodiments, the 2'-O-methylation is located at one or more of positions 1-23 of the sequences shown in SEQ ID NO: 1 and / or SEQ ID NO: 2.

[0099] In some embodiments, the 2'-O-methylation is located at one or more positions 1 and 4-23 of the sequence shown in SEQ ID NO: 1 and / or SEQ ID NO: 2. In some embodiments, the 2'-O-methylation is located at positions 1 and 4-23 of the sequence shown in SEQ ID NO: 2. An example is the antisense strand of mimic 6.

[0100] In some embodiments, the 2'-O-methylation is located at one or more of positions 1, 4-12, and 14-23 of the sequence shown in SEQ ID NO: 1 and / or SEQ ID NO: 2. In some embodiments, the 2'-O-methylation is located at one or more of positions 1, 4-12, and 14-23 of the sequence shown in SEQ ID NO: 1. Exemplarily, the positive strand of mimic 6 is visible.

[0101] In some embodiments, the 2'-O-methylation is located at positions 1, 9-12, and 14-16 of the sequence shown in SEQ ID NO: 1 and / or SEQ ID NO: 2; and one or more of positions 20-23. Exemplarily, the 2'-O-methylation is located at positions 1, 9-12, and 14-16 of the sequence shown in SEQ ID NO: 1 and / or SEQ ID NO: 2; and:

[0102] The 20th to 23rd position, the 21st to 23rd position, the 20th to 23rd position, or the 20th to 22nd position.

[0103] In some embodiments, the 2'-O-methylation is located at positions 1, 9-12, and 14-16 of the sequence shown in SEQ ID NO: 1; and positions 21-23.

[0104] In some embodiments, the 2'-O-methylation is located at positions 1, 9-12, and 14-16 of the sequence shown in SEQ ID NO: 2; and positions 20-23, or positions 20-22.

[0105] In some embodiments, the 2'-O-methylation is located at positions 1-2 and 22-23 of the sequence shown in SEQ ID NO: 1 and / or SEQ ID NO: 2; and one or more of the spacer positions in positions 3-21.

[0106] Unless otherwise specified, the term "spacer" in this application refers to a non-contiguous site in a sequence. The spacer referred to can be separated from the site by 1, 2, 3, 4, or more positions, as long as they are not consecutive. For example, the 1st and 3rd positions, or the 4th and 8th positions, are spacers to each other.

[0107] In some embodiments, the spacer positions in positions 3-21 are one or more of positions 4, 6, 8, 10, 12, 14, 16, 18, and 20. Exemplarily, the 2'-O-methylation is located at positions 1-2 and 22-23 of the sequences shown in SEQ ID NO: 1 and / or SEQ ID NO: 2; and positions 4, 6, 10, 12, 14, 16, 18, and 20.

[0108] In some implementations, the 3rd to 21st interval bits are one or more of the 3rd, 5th, 7th, 9th, 11th, 13th, 15th, 17th, 19th and 21st bits.

[0109] In some embodiments, the thiophosphate and the 2'-O-methylation may be located at the same site or at different sites.

[0110] In some embodiments, the sense strand and / or the antisense strand simultaneously comprise thiophosphate modification and 2'-O-methylation modification. The thiophosphate and the 2'-O-methylation may be located at partial sites in the sense strand and / or the antisense strand, respectively, or they may be located at the same site simultaneously.

[0111] In some embodiments, the thiophosphate and the 2'-O-methylation are simultaneously located at the ends of the sense chain and / or the antisense chain, exemplarily at one or more of the 1st, 2nd, 21st, 22nd and 23rd positions.

[0112] In some implementations, the antisense chain contains the following sequence:

[0113] sCm.UsAsCUAAAAmCmAmUmGGmAmAmGCACm.sUm.sUm.A (Answer chain of Mimic 12); or sCm.UsAsCUAAAAmCmAmUmGGmAmAmGCACm.sUm.sUm.sAm (Answer chain of mimic 13).

[0114] In some embodiments, the 2'-fluorine substitution modification occurs in nucleotides containing various types of bases.

[0115] In some embodiments, the 2'-fluorine substitution modification occurs in the nucleotide containing a subset of the bases. Exemplarily, the 2'-fluorine substitution modification occurs in the nucleotide containing uracil in SEQ ID NO: 1 and / or SEQ ID NO: 2, or in the nucleotide containing adenine, or in the nucleotide containing cytosine.

[0116] In some embodiments, the thiophosphate and the 2'-fluorine substitution modification are located at different sites.

[0117] In some embodiments, the 2'-fluorine substitution modification is located at least in the spacer positions of positions 3-21 of the sequences shown in SEQ ID NO: 1 and / or SEQ ID NO: 2. Exemplarily, it is located at least in one or more of positions 3, 5, 7, 9, 11, 13, 15, 17, 19, and 21 of the sequences shown in SEQ ID NO: 1 and / or SEQ ID NO: 2; or, at least in one or more of positions 4, 6, 8, 10, 12, 14, 18, and 20 of the sequences shown in SEQ ID NO: 1 and / or SEQ ID NO: 2.

[0118] In some embodiments, the 2'-fluorine substitution modification is located at at least one or more of the 3rd, 5th, 7th, 9th, 11th, 13th, 15th, 17th, 19th, and 21st positions of the sequence shown in SEQ ID NO: 1. In some embodiments, the 2'-fluorine substitution modification is located at the 3rd, 5th, 7th, 8th, 9th, 11th, 13th, 15th, 17th, 19th, and 21st positions of the sequence shown in SEQ ID NO: 1.

[0119] In some embodiments, the 2'-fluorine substitution modification is located at positions 4, 6, 8, 10, 12, 14, 18, and 20 of the sequence shown in SEQ ID NO: 2.

[0120] In some embodiments, the 2'-O-methylation and the 2'-fluorine substitution are located at the same or different sites. In some embodiments, the 2'-O-methylation and the 2'-fluorine substitution are located at different sites.

[0121] In some embodiments, the 2'-O-methylation and the 2'-fluorine substitution are alternated at positions 3-21 of the sequences shown in SEQ ID NO: 1 and / or SEQ ID NO: 2. For example, the 2'-O-methylation is located at odd (or even) positions 3-21, and the 2'-fluorine substitution is located at even (or odd) positions 3-21.

[0122] In some embodiments, the 2'-fluorine substitution modification is located at at least one or more of the spacer positions in positions 3-21 of the sequence shown in SEQ ID NO: 1, and the 2'-O-methylation is located at positions 1-2 and 22-23 of the sequence shown in SEQ ID NO: 1; and at one or more of the spacer positions in positions 3-21.

[0123] For example, when the 2'-fluorine substitution modification is located at an odd position in positions 3-21 of the sequence shown in SEQ ID NO: 1, the 2'-O-methylation is located at an even position in positions 3-21 of the sequence shown in SEQ ID NO: 1; or when the 2'-fluorine substitution modification is located at least at an odd position in positions 3-21 of the sequence shown in SEQ ID NO: 1, the 2'-O-methylation is located at a site in positions 3-21 of the sequence shown in SEQ ID NO: 1 that does not contain a 2'-fluorine substitution modification; and,

[0124] One or more of positions 1-2 and 22-23 (e.g., position 1-2) of the sequence shown in SEQ ID NO: 1 contain thiophosphate.

[0125] In some embodiments, the 2'-fluorine substitution modification is located at at least one or more of the spacer positions in positions 3-21 of the sequence shown in SEQ ID NO: 2, and the 2'-O-methylation is located at positions 1-2 and 22-23 of the sequence shown in SEQ ID NO: 2, as well as one or more of the spacer positions in positions 3-21.

[0126] For example, when the 2'-fluorine substitution modification is located at an even position in positions 3-21 of the sequence shown in SEQ ID NO: 2, the 2'-O-methylation is located at an odd position in positions 3-21 of the sequence shown in SEQ ID NO: 2; and one or more positions (e.g., positions 1-2 and 22-23) of positions 1-2 and 22-23 of the sequence shown in SEQ ID NO: 2 contain a thiophosphate.

[0127] For example, the 2'-O-methylation is located at least at odd positions in positions 3-21 of the sequence shown in SEQ ID NO: 2, the 2'-fluorine substitution modification is located at positions 3-21 of the sequence shown in SEQ ID NO: 2 that do not have 2'-O-methylation modification, and one or more positions (e.g., positions 1-2 and 22-23) of positions 1-2 and 22-23 of the sequence shown in SEQ ID NO: 2 contain thiophosphate.

[0128] In some embodiments, the 2'-fluorine substitution modification of the sequence shown in SEQ ID NO: 1 is located at at least one or more of the spacer positions in positions 3-21 of the sequence, and the 2'-O-methylation is located at positions 1-2 and 22-23 of the sequence; and at positions 3-21 without 2'-fluorine substitution modification; and in the sequence shown in SEQ ID NO: 2, the 2'-O-methylation is located at at least one or more of the spacer positions in positions 1-2 and 22-23 of the sequence; and at positions 3-21 without 2'-O-methylation.

[0129] In some embodiments, the 2'-O-methylation is located at positions 1-2 and 22-23, and positions 4, 6, 8, 10, 12, 14, 16, 18, and 20 of the sequence shown in SEQ ID NO: 1 and / or SEQ ID NO: 2; and the 2'-fluorine substitution is located at positions 3, 5, 7, 9, 11, 13, 15, 17, 19, and 21 of SEQ ID NO: 1 and / or SEQ ID NO: 2.

[0130] In some embodiments, the 2'-O-methylation is located at positions 1-2 and 22-23, and positions 4, 6, 10, 12, 14, 16, 18, and 20 of the sequence shown in SEQ ID NO: 1; and the 2'-fluorine substitution is located at positions 3, 5, 7, 8, 9, 11, 13, 15, 17, 19, and 21 of SEQ ID NO: 1.

[0131] In some embodiments, the 2'-O-methylation is located at positions 1-2 and 22-23, and positions 3, 5, 7, 9, 11, 13, 15, 17, 19, and 21 of the sequence shown in SEQ ID NO: 2; and the 2'-fluorine substitution is located at positions 4, 6, 8, 10, 12, 14, 16, 18, and 20 of SEQ ID NO: 2.

[0132] In some embodiments, the 2'-O-methylation is located at positions 1-2 and 22-23, and positions 3, 5, 7, 9, 11, 13, 15, 16, 17, 19, and 21 of the sequence shown in SEQ ID NO: 2; and the 2'-fluorine substitution is located at positions 4, 6, 8, 10, 12, 14, 18, and 20 of SEQ ID NO: 2.

[0133] In some embodiments, the sense chain and / or the antisense chain simultaneously comprise 2'-O-methylation, 2'-fluorine substitution, and a thiophosphate. The thiophosphate, the 2'-O-methylation, and the 2'-fluorine substitution satisfy the above-described limitations.

[0134] In some implementations, the justice chain has the following modified sequence:

[0135] sUm.sAm.AfGmUfGmCfUmUfCmCfAmUfGmUfUmUfUmAfGmUfAmGm (Chain of Justice in Mimic 23); or sUm.sAm.AfGmUfGmCfUfUfCmCfAmUfGmUfUmUfUmAfGmUfAmGm (Chain of Justice in Mimic 25).

[0136] In some implementations, the antisense chain has the following modified sequence:

[0137] sCm.sUm.AfCmUfAmAfAmAfCmAfUmGfGmAfAmGfCmAfCmUf.sUm.sAm (Answer chain of Mimic 22); sCm.sUm.AmCfUmAfAmAfAmCfAmUfGmGfAmAfGmCfAmCfUm.sUm.sAm (Answer chain of Mimic 24); or, sCm.sUm.AmCfUmAfAmAfAmCfAmUfGmGfAmAmGmCfAmCfUm.sUm.sAm (Answer chain of Mimic 26).

[0138] The sense and antisense strands can be combined arbitrarily to form double-stranded miRNAs. Examples of double-stranded miRNAs are Mimic 23-26.

[0139] LNA modification

[0140] In some implementations, the justice chain and / or the antisense chain further include LNA modifications.

[0141] In some embodiments, the sense strand and / or the antisense strand comprises a thiophosphate, a 2'-O-methylation, and an LNA modification. The thiophosphate, the 2'-O-methylation, and the LNA modification may be located in the same or different nucleotides.

[0142] In some embodiments, the LNA modification excludes other modifications besides the LNA modification at the site. For example, in some embodiments, the thiophosphate and the 2'-O-methylation are located on the same or different nucleotides, and the LNA modification is located on a nucleotide that does not have thiophosphate and / or 2'-O-methylation modifications.

[0143] In some embodiments, the LNA modification is located at one or more positions in positions 1-8 of the sequence shown in SEQ ID NO: 1 and / or SEQ ID NO: 2. In some embodiments, the LNA modification is located at least in the spacer positions in positions 1-8 of the sequence shown in SEQ ID NO: 2. Exemplarily, the LNA modification is located at positions 2, 4, 6, and 8 of the sequence shown in SEQ ID NO: 2; alternatively, the LNA modification excludes other modifications besides the LNA modification at the location.

[0144] In some embodiments, the sense chain and / or the antisense chain simultaneously comprise LNA modification, 2'-O-methylation modification, and thiophosphate as described above.

[0145] In some embodiments, all sites other than those with LNA modification are 2'-O-methylated. For example, except for positions 2, 4, 6, and 8 which are LNA-modified only, all other positions are 2'-O-methylated. In some embodiments, the sites containing LNA and 2'-O-methylation are as shown in the positive strand of mimic16.

[0146] In some embodiments, the positive chain simultaneously includes LNA modification, 2'-O-methylation modification, and thiophosphate as described above.

[0147] In some implementations, the sequence of the justice chain is as follows: sUm.AlnaAGlnaUGlnaCUlnaUmCmCmAmUGmUmUmUUAGUm.sAm.sGm (the justice chain of mimic 12).

[0148] DNA modification

[0149] In some embodiments, the sense and / or antisense strands of the double-stranded miRNA further contain DNA modifications.

[0150] In some embodiments, the double-stranded miRNA comprises phosphate thioester, 2'-O-methylation, and DNA modification.

[0151] In some embodiments, the double-stranded miRNA comprises phosphate thioester, 2'-O-methylation, LNA modification, and DNA modification.

[0152] In some embodiments, the DNA modification is replaced with thymine.

[0153] In some embodiments, the DNA modification involves replacing uracil with thymine.

[0154] In some implementations, the DNA modification excludes modifications other than LNA modification at the site.

[0155] In some embodiments, at least one uracil site in the sequence shown in SEQ ID NO: 1 has a DNA modification. In some embodiments, one, any two (e.g., positions 5 and 8, 5 and 13), any three (e.g., positions 5, 8, and 13), any four (e.g., positions 8, 13, 17, and 18), or five of the positions in the sequence shown in SEQ ID NO: 1 are replaced with thymine. In some embodiments, the 5th, 8th, 13th, 17th, or 18th position in the sequence shown in SEQ ID NO: 1 is replaced with thymine. In some embodiments, the 5th, 8th, 17th, and 18th positions in the sequence shown in SEQ ID NO: 1 are replaced with thymine. In some embodiments, all uracils in the sequence shown in SEQ ID NO: 1 are replaced with thymine. In some embodiments, the positive strand comprises a sequence as shown in the mimic 14 positive strand.

[0156] In some embodiments, at least one uracil site in the sequence shown in SEQ ID NO: 2 has the DNA modification. In some embodiments, one or more of positions 5, 8, 13, 17, and 18 of the sequence shown in SEQ ID NO: 2 are replaced with thymine. In some embodiments, positions 5, 8, 13, 17, or 18 are replaced with thymine. In some embodiments, all uracils in the sequence shown in SEQ ID NO: 2 are replaced with thymine. In some embodiments, the antisense strand comprises a sequence as shown in the mimic 14 antisense strand.

[0157] In some embodiments, all uracil in the sequence shown in SEQ ID NO: 1 is replaced with thymine, and all uracil in the sequence shown in SEQ ID NO: 2 is replaced with thymine.

[0158] In some implementations, the justice chain comprises a sequence as shown in the mimic 14 justice chain, and the antisense chain comprises a sequence as shown in the mimic 14 antisense chain.

[0159] In some embodiments, the double-stranded miRNA comprises phosphate thioester, 2'-O-methylation, and DNA modification.

[0160] In some implementations, the justice chain comprises the following sequence:

[0161] sUm.AsAsGUGCTUmCmCmAmUGmUmUmUUAGUm.sAm.sGm (the justice chain of mimic 10), or sUm.AsAsGTGCTUmCmCmAmUGmUmUmTTAGUm.sAm.sGm (the justice chain of mimic 22).

[0162] In some implementations, the antisense chain comprises the following sequence:

[0163] sCm.UsAsCTAAAAmCmAmUmGGmAmAmGCACm.sUm.sUm.sAm (the antisense chain of mimic 10).

[0164] In some embodiments, the double-stranded miRNA comprises a phosphate thioester, 2'-O-methylation, LNA modification, and DNA modification. The phosphate thioester, 2'-O-methylation, LNA modification, and DNA modification are defined as described above.

[0165] In some implementations, the justice chain comprises the following sequence: sUm.AlnaAGlnaTGlnaCUlnaUmCmCmAmTGmUmUmTTAGUm.sAm.sGm (the justice chain of mimic 15).

[0166] End modification

[0167] In some embodiments, the sense strand and / or the antisense strand of the double-stranded miRNA further comprises end modifications.

[0168] In some embodiments, the end modification is a 3' end with a 5' NN 3' structure protrusion, wherein each occurrence of N is independently selected from the group consisting of adenine (A), thymine (T), cytosine (C), guanine (G) and uracil (U).

[0169] The protruding end may or may not be decorated.

[0170] For example, the protruding end is selected from the group consisting of 5' Nm Nm 3', 5' sN sN 3', 5' Nm sN 3', 5' sN Nm 3', 5' sNm sNm 3', 5' sNm Nm 3', 5' Nm sNm 3', 5' sNm sNm 3', and 5' sN sNm 3'; where "m" represents 2'-O-methylation and "s" represents thiophosphate.

[0171] The NN can be selected from the group consisting of UG, TT, AC and AA.

[0172] In some specific embodiments, the protruding end is selected from the group consisting of 5' sTm sTm 3', 5' sUm sGm 3', 5' sAm sCm 3', and 5' sAm sAm 3'. For example, the protruding end is 5' sTm sTm 3', 5' sUm sGm 3', 5' sAm sCm 3', or 5' sAm sAm 3'.

[0173] In some implementations, the protruding end is located at the 3' end of the antisense chain.

[0174] In some implementations, the protruding end is located at the 3' end of sCm.UsAsCUAAAAmCmAmUmGGmAmAmGCACm.sUm.sUm.sAm (the antisense chain of mimic 13).

[0175] In some implementations, the antisense chain contains the following structure: sCm.UsAsCUAAAAmCmAmUmGGmAmAmGCACm.sUm.sUm.sAm.sUm.sGm (antisense chain of mimic 17), or sCm.UsAsCUAAAAmCmAmUmGGmAmAmGCACm.sUm.sUm.sAm.sAm.sCm (antisense chain of mimic 19).

[0176] In some implementations, the protruding end is located at the 3' end of sCm.sUm.AmCfUmAfAmAfAmCfAmUfGmGfAmAmGmCfAmCfUm.sUm.sAm (the antisense chain of mimic 26).

[0177] In some implementations, the antisense chain has the following modified sequence:

[0178] sCm.sUm.AmCfUmAfAmAfAmCfAmUfGmGfAmAmGmCfAmCfUm.sUm.sAm sUm.sGm (the antisense chain of mimic27);

[0179] sCm.sUm.AmCfUmAfAmAfAmCfAmUfGmGfAmAmGmCfAmCfUm.sUm.sAm sTm.sTm (the antisense chain of mimic28);

[0180] sCm.sUm.AmCfUmAfAmAfAmCfAmUfGmGfAmAmGmCfAmCfUm.sUm.sAm sAm.sCm (the antisense chain of mimic29); or

[0181] sCm.sUm.AmCfUmAfAmAfAmCfAmUfGmGfAmAmGmCfAmCfUm.sUm.sAm sAm.sAm (the antisense chain of mimic30);

[0182] And the justice chain has the following sequence: sUm.sAm.AfGmUfGmCfUfUfCmCfAmUfGmUfUmUfUmAfGmUfAmGm (the justice chain of mimic 25).

[0183] In some embodiments, the double-stranded miRNA is selected from the group consisting of mimics 1 to 30 in Table 1 above. In some embodiments, the double-stranded miRNA is mimic 1. In some embodiments, the double-stranded miRNA is mimic 2. In some embodiments, the double-stranded miRNA is mimic 3. In some embodiments, the double-stranded miRNA is mimic 4. In some embodiments, the double-stranded miRNA is mimic 5. In some embodiments, the double-stranded miRNA is mimic 6. In some embodiments, the double-stranded miRNA is mimic 7. In some embodiments, the double-stranded miRNA is mimic 8. In some embodiments, the double-stranded miRNA is mimic 9. In some embodiments, the double-stranded miRNA is mimic 10. In some embodiments, the double-stranded miRNA is mimic 11. In some embodiments, the double-stranded miRNA is mimic 12. In some embodiments, the double-stranded miRNA is mimic 13. In some embodiments, the double-stranded miRNA is mimic 14. In some embodiments, the double-stranded miRNA is mimic 15. In some embodiments, the double-stranded miRNA is mimic 16. In some embodiments, the double-stranded miRNA is mimic 17. In some embodiments, the double-stranded miRNA is mimic 18. In some embodiments, the double-stranded miRNA is mimic 19. In some embodiments, the double-stranded miRNA is mimic 20. In some embodiments, the double-stranded miRNA is mimic 21. In some embodiments, the double-stranded miRNA is mimic 22. In some embodiments, the double-stranded miRNA is mimic 23. In some embodiments, the double-stranded miRNA is mimic 24. In some embodiments, the double-stranded miRNA is mimic 25. In some embodiments, the double-stranded miRNA is mimic 26. In some embodiments, the double-stranded miRNA is mimic 27. In some embodiments, the double-stranded miRNA is mimic 28. In some embodiments, the double-stranded miRNA is mimic 29. In some embodiments, the double-stranded miRNA is mimic 30.

[0184] In some embodiments, the sense chain and / or the antisense chain further comprises at least one or more terminal groups.

[0185] In some embodiments, the terminal group is a 3' terminal group.

[0186] In some embodiments, the 3' terminal group includes, but is not limited to, one or more of the group consisting of cholesterol, bile acids, fatty acids, polyethylene glycol, antibodies, polymers, and N-acetylgalactosamine (GalNAC).

[0187] I do not wish to be limited by any theory, but I believe that the addition of terminal groups at least facilitates the uptake of miRNA by cells.

[0188] The polymer described in this application may be, for example, a cationic polymer.

[0189] Exemplary polymers include, but are not limited to, PAMAM, PEI, PLL, and PBAEs.

[0190] In some embodiments, the terminal group is a fluorescent or biotinylated label at the 3' or 5' end.

[0191] In some embodiments, the 3' terminal group is cholesterol. Optionally, the cholesterol modification is exemplarily connected as follows:

[0192] .

[0193] A second aspect of this application provides a pharmaceutical composition comprising a double-stranded miRNA as described in the first aspect, and a pharmaceutically acceptable carrier.

[0194] A third aspect of this application provides an anti-aging product comprising the double-stranded miRNA as described in the first aspect.

[0195] In some embodiments, the double-stranded miRNA may be one or more of mimic10, mimic12, mimic13, mimic17, mimic19, mimic22-26, mimic28, and mimic29.

[0196] A fourth aspect of this application provides the use of the double-stranded miRNA as described in the first aspect in the preparation of anti-aging products or medicaments for aging-related diseases.

[0197] Unless otherwise specified, the term "anti-aging" in this application refers to inhibiting or delaying the aging process of the body, for example, anti-skin aging. Skin aging phenomena include, but are not limited to, skin laxity (such as wrinkles, fine lines, etc.), decreased elasticity, uneven skin tone (such as age spots, etc.), dull skin tone, dry skin, enlarged pores, and thinning skin.

[0198] In some embodiments, the double-stranded miRNA may be one or more of mimic5, mimic10, mimic12-15, mimic17-19, and mimic22-30.

[0199] In some implementations, the age-related diseases mentioned include Alzheimer's disease.

[0200] In a fifth aspect of this application, the use of the double-stranded miRNA as described in the first aspect is provided in the preparation of a medicament for the treatment of Alzheimer's disease.

[0201] In some embodiments, the double-stranded miRNA may be one or more of mimic5, mimic10, mimic12-14, mimic16-19, mimic22-26, and mimic27-30.

[0202] In a sixth aspect of this application, the use of the double-stranded miRNA as described in the first aspect is provided in the preparation of a medicament for treating articular cartilage injury.

[0203] In some embodiments, the double-stranded miRNA may be one or more of mimic5, mimic19, mimic22, mimic26, mimic28, and mimic29.

[0204] In a seventh aspect of this application, the use of the double-stranded miRNA as described in the first aspect is provided in the preparation of a medicament for the treatment of diabetes.

[0205] In some embodiments, the double-stranded miRNA may be one or more of mimic5, mimic10, mimic12, mimic13, mimic19, mimic22, mimic23, mimic25, mimic26, mimic28, and mimic29.

[0206] In an eighth aspect of this application, the use of the double-stranded miRNA as described in the first aspect is provided in the preparation of a medicament for non-alcoholic fatty liver disease.

[0207] In some embodiments, the double-stranded miRNA may be one or more of mimic5, mimic10, mimic12, mimic13, mimic19, mimic22, mimic23, mimic25, mimic26, mimic28, and mimic29.

[0208] In a ninth aspect of this application, the use of the double-stranded miRNA as described in the first aspect is provided in the preparation of a medicament for the treatment of cirrhosis.

[0209] In some embodiments, the double-stranded miRNA may be one or more of mimic5, mimic12, mimic13, mimic19, mimic24-26, and mimic29.

[0210] In a tenth aspect of this application, the use of the double-stranded miRNA as described in the first aspect is provided in the preparation of a medicament for treating androgenetic alopecia.

[0211] In some embodiments, the double-stranded miRNA may be one or more of mimic5, mimic6, mimic10, mimic12, mimic13, mimic19, mimic22-26, and mimic28-30.

[0212] In the eleventh aspect of this application, the use of the double-stranded miRNA as described in the first aspect is provided in the preparation of a medicament for treating chronic nephritis.

[0213] In some embodiments, the double-stranded miRNA may be one or more of mimic5, mimic12, mimic13, mimic17-19, mimic23-26, mimic28, and mimic29.

[0214] In some embodiments, the method of administration of the anti-aging product or the drug is selected from the group consisting of intravenous, intramuscular, intra-arterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, tracheal, subcutaneous, subepidermal, intra-articular, subcapsular, subarachnoid, spinal, and intrasternal injection and infusion.

[0215] In a twelfth aspect of this application, a method is provided for treating Alzheimer's disease, articular cartilage damage, diabetes, non-alcoholic fatty liver disease, cirrhosis, androgenetic alopecia, or chronic nephritis, the method comprising administering to a subject the double-stranded miRNA as described in the first aspect.

[0216] In the thirteenth aspect of this application, liposome nanoparticles comprising double-stranded miRNA as described in the first aspect are provided.

[0217] Example 1 miR302 target

[0218] Clipping is a method primarily used to isolate and identify RNAs, microRNAs, and protein complexes within ribonucleoprotein complexes in cells. This method determines whether certain RBPs bind to specific RNAs and immunoprecipitates the RBPs and their bound RNA. Crosslinking-immunoprecipitation (CLIP) and PAR-CLIP techniques expose living cells to UV light, causing RNA-protein binding. Specific proteins and their bound RNAs can then be separated using co-immunoprecipitation, allowing for further identification of RNA types via high-throughput sequencing. PAR-CLIP-Seq applied to miRNA target gene analysis significantly reduces the false-positive prediction frequency of miRNA binding sites and narrows the search space for miRNA binding sites. It can identify binding sites of the AGO2 protein on different RNAs across the entire genome.

[0219] LO2 cells transfected with miR-302b mimics were irradiated with 254 mJ of ultraviolet light, and cells were scraped from 15 cm plates. Ago2 clip-seq was performed as previously described. Cell lysates were immunoprecipitated with anti-Ago2 antibody (Abcam, ab186733) to enrich Ago2 protein and its binding RNA. Immunoprecipitated RNA was extracted with TRIzol, treated with DNase I, and the purified RNA was reverse transcribed to synthesize cDNA for high-throughput sequencing. Based on sequence alignment analysis, the expected binding site of miR-302b was determined (see [link to relevant documentation]). Figure 2 The study found that miR-302b has a strong binding affinity to CDKN1A (free energy MEF = -12.84 kcalmol; the lower the MEF value, the stronger the binding affinity). However, mutating the 3'UTR region binding site of CDKN1A (from GGCACTT to CCGTGAA) increases its free energy to -6.1 kcalmol and decreases its binding affinity, demonstrating the specificity of miR-302b binding to CDKN1A.

[0220] CDKN1A is a CDK (cyclin-dependent kinase) inhibitor that maintains cell cycle arrest by binding to CDK2, CDK4, and CDK6, preventing these kinases from phosphorylating cyclins. CDKN1A has been widely used as a major marker of senescent cells. This role of CDKN1A is one of the cell's responses to internal and external stimuli such as DNA damage and oxidative stress. During cellular senescence, p21 expression typically increases, and this elevated CDKN1A level causes cells to arrest in the G1 phase, preventing them from entering the S phase for DNA replication. This cell cycle arrest is a classic characteristic of senescent cells, marking the loss of growth and proliferation capacity after physiological or pathological stress. In addition to maintaining cell cycle arrest in senescent cells, CDKN1A also plays a prominent role in establishing SASP through protein Rb-dependent transcription (including selected SMAD and STAT transcription factors). Although this transcriptional program remains active in senescent cells, CDKN1A initiates this program as the first response to cellular stress occurring concurrently with cell cycle arrest. The resulting immediate early secretory proteome is what they call the CDKN1A-activated secretory phenotype.

[0221] Example 2: Synthesis of miR302-mimic

[0222] A series of small nucleic acids with different modifications were designed and synthesized.

[0223] The modification groups are as follows:

[0224] Table 2

[0225]

[0226] Table 2 (continued)

[0227]

[0228]

[0229] Table 2 (continued)

[0230]

[0231] Preparation process:

[0232] The basic preparation process of small nucleic acid single-stranded molecules is as follows: Figure 1 As shown.

[0233] Step 1a. Synthesis using an OP100 / OS50 solid-state synthesizer: including deprotection, coupling, oxidative / thiolated modifications, capping, etc. Specifically:

[0234] Prepare a DCA toluene solution as a deprotecting agent, a 0.25M ETT (0.25M, 5-ethylthiotetrazole N / A acetonitrile) solution as a coupling agent, a 0.05M iodine-pyridine / aqueous solution as an oxidizing agent, hydroflavin as a thioating agent, and a CH3CN / imidazolium solution containing 20% ​​acetyl chloride as a capping reagent. Place these reagents in the designated positions on the OP100 / OS50 synthesizer. Set the synthesis program, input the specified oligonucleotide base sequence, and begin the cyclic oligonucleotide synthesis. Each coupling step takes 6 minutes, and the coupling time for the L and S monomers corresponding to the galactose ligand is 10-20 minutes. After automatic cycling, the oligonucleotide solid-phase synthesis is complete.

[0235] Step 1b. Ammonolysis and desilication.

[0236] Ammonolysis was performed using 160 mL / mmol AMA at 60°C for 3 hours. Desilication was performed using 20 mL / mmol DMSO, 280 mL / mmol TEA, and 93.3 mL / mmol TEA*3HF (≤15°C) at 40°C for 4 hours. After the desilication reaction, the system was diluted with purified water, and the pH was adjusted to approximately 7.0 with an aqueous acetic acid solution. The system was then centrifuged to allow sedimentation, and the solid was collected.

[0237] Step 1c. Purification.

[0238] Agilent HPLC purification system, sample dissolution and loading at 45℃ with hot ethanol, mobile phase A: 200mM TEAA in H2O, mobile phase B: preparative acetonitrile, elution gradient: 20-80% for 90 min, linear flow rate: 160-200 cm / h (10 mL / min), purification column: C8 or C18 column, column temperature: 40℃.

[0239] Step 1d. Desalting and freeze-drying.

[0240] Purified water was used for ultrafiltration desalination, and the equipment was a 3 kDa TFF membrane-encapsulated ultrafiltration desalination system.

[0241] Finally, double-stranded small nucleic acids were prepared by annealing and freeze-drying.

[0242] Example 3: Target Inhibition Rate

[0243] Based on previous data, a cell senescence model was established using the following method: well-grown p21-YFP LO2 cells were treated with stress medium (complete medium containing 50 nM Dox) for 48 h, and then cultured in normal medium for 48 h. Flow cytometry (FACSCalibur, BD Biosciences) was used to sort individual SnCs for p21 expression; the sorted cells were identified as uniformly senescent cells.

[0244] LO2 cells and senescent LO2 cells were cultured in DMEM medium containing 10% fetal bovine serum at 37°C with 5% CO2. When the cells were in the logarithmic growth phase and in good condition (70% confluence), they were transfected with transfection reagents (mimic1-10, miRNA302b, NC). The cell concentration was adjusted to 1×10⁻⁶ cells / year. 6 Add 1 ml of cell solution and 5 μL of Lipofectamine® RNAiMAX Reagent transfection reagent to each well of a 6-well plate. After incubating at room temperature for 5 min, add 5 μL of 10 μM siRNA and incubate at 37°C and 5% CO2 for 48 h.

[0245] In addition to the experimental group, the following control groups were set up for each cell plating session: NC as the negative control (without siRNA), Mock as the transfection reagent control group, and untreated control group (without siRNA). Both the experimental and control groups were replicated three times.

[0246] Real-time quantitative PCR analysis of target mRNA levels

[0247] 1. Cells were lysed 48 hours after transfection, and total RNA was extracted using the Trizol method.

[0248] 2. Reverse transcription (Takara kit, catalog number 638313).

[0249] 3. Quantitative Real-Time PCR

[0250] Using the GAPDH gene as an internal reference, real-time quantitative PCR was performed using the SYBR Premix (2×) Real-time PCR kit, and the PCR reaction was conducted using a Rotor-Gene-Q real-time PCR instrument (Qiagen, USA). Primers used were:

[0251] CDKN1A:

[0252] Forward PrimerACATCGCCAAGGAAAAACGC (SEQ ID NO: 5)

[0253] Reverse PrimerGTCTGTTTCGGTACTGTCATCC (SEQ ID NO: 6)

[0254] GAPDH:

[0255] Forward PrimerTGTGGGCATCAATGGATTTGG (SEQ ID NO: 7)

[0256] Reverse PrimerACACCATGTATTCCGGGTCAAT (SEQ ID NO: 8)

[0257] After the PCR reaction, the Ct error for 9 replicates of a sample (3 transfection replicates per sample, 3 replicates for qPCR) was ±0.5. The average expression levels of the target genes of the preferred siRNA relative to the NC group (the relative mRNA expression level of the NC group was 1) are shown in the table below:

[0258] Table 3

[0259]

[0260] The results showed that, compared with natural miRNA, the inhibitory effect on the target decreased after some modifications, while it increased after other modifications. The addition of thio-modification and methylation modifications had little effect on the knockdown ability of the two targets. Further addition of LNA modification, fluorination modification, replacing part of the RNA sequence with DNA sequence, and adding protective bases to the antisense strand increased the knockdown ability of the target.

[0261] Furthermore, after sorting, the cells were identified as uniformly senescent cells, and the cell concentration was adjusted to 1×10⁻⁶. 6 1 ml of cell solution and 5 μL of Lipofectamine® RNAiMAX Reagent transfection reagent were added to each well of a 6-well plate. After incubation at room temperature for 5 min, 5 μL of 100 nM siRNA was added, and the plates were incubated at 37°C and 5% CO2. The re-division of senescent cells was observed using a high-content laser confocal cell imaging system (OperaPhenix, PerkinElmer Enterprise Management, Ltd.) (one image was taken every hour for 72 hours). Cell division events were recorded in the field of view, and the experiment was repeated three times. The number of cells in the field of view was summed. The results are as follows:

[0262] Table 4

[0263]

[0264] The results showed that under low concentrations of small nucleic acids transfected, no cell proliferation events were detected in the NC group, miRNA302b group, mimic1-3, mimic7-8, and mimic21 group. The number of cells in the field of view was close to the number of seeded cells, indicating that senescent cells hardly proliferated, and the above modifications failed to achieve the biological functions of small nucleic acids. mimic4-6 showed a total of less than 5 cell proliferation events, indicating that some senescent cells under these experimental conditions underwent "reverse aging." mimic8-10 were modified by partially replacing U with deoxyribonucleic acid T in mimic5. Groups 8-9 showed worse results than the unmodified group, while group 10 showed 10 division events and a significantly increased number of cells in the field of view, indicating... In some cases, replacing RNA with deoxyribonucleic acid (DNA) can improve the biological function of small nucleic acids. Furthermore, some bases in mimic12-20 have been modified with LNA. Compared with mimic10, some of these modifications further improve their biological function. For example, mimic19, which adds a modified 5'-AC-3' to the antisense strand of mimic13, showed more than 300 cells in 5 fields of view and 17 clear proliferation phenomena were observed. However, in other cases, it reduced its biological function. Furthermore, mimic11 and mimic22-30 have been modified with fluorination at different sites, and some of these modifications further improve their biological function, such as mimic26 and 29.

[0265] Example 4 Stability Testing

[0266] Human serum was obtained by separating peripheral blood from volunteers; C57 mouse serum and SD rat serum were obtained by separating blood from the orbital cavity. Tris-base was purchased from Sigma-Aldrich; hexafluoroisopropanol (HFIP) and diisopropylamine (DIPA) were both products of Sigma-Aldrich; methanol was chromatographically pure and a product of Sigma-Aldrich; other reagents were analytically pure.

[0267] Solution preparation

[0268] (1) 5% ammonia solution: Take 4 ml of 25% ammonia solution and add it to 16 ml of deionized water;

[0269] (2) 50 μM siRNA solution: Take 46 μL of 10 mg / ml siRNA stock solution (containing 5% methanol) and add it to 660.5 μL of deionized water.

[0270] Stability testing of mimic in different matrices

[0271] Take 90 μL of 50 μM siRNA sample solution and add it to 810 μL of deionized water, human serum, rat serum, and mouse serum, respectively. Take 90 μL of 50 μM siRNA control solution and add it to mouse serum. After incubating in a 37℃ water bath for 0, 0.25, 0.5, 1, and 2 h, take 100 μL of each sample for pretreatment. Except for the deionized water sample which was directly injected for analysis, the remaining 100 μL of biological matrix samples were added to 250 μL of 5% ammonia solution, mixed well, and then 100 μL of liquid-liquid extraction buffer (phenol-chloroform-isoamyl alcohol mixture) was added. After mixing well, the samples were centrifuged at 16000×g for 10 min at 4℃. Take 332 μL of supernatant, and then blow the supernatant with nitrogen to about 30 μL at room temperature. Add ultrapure water to 100 μL. After reconstitution, the sample was centrifuged at 16000×g for 10 min at 4℃, and the supernatant was collected for analysis.

[0272] Liquid chromatography-mass spectrometry (LC-MS): Mimic stability was detected using an ultra-high performance liquid chromatography / ion trap mass spectrometry system (Waters Acquity UPLC / ThermoFisher LTQ).

[0273] Chromatographic conditions: Column: Oligonucleotide BEH C18 column (2.5 μm, 2.1 mm × 50 mm); Mobile phase: A (10 mM DIPA, 25 mM HFIP in water) and B (10 mM DIPA, 25 mM HFIP in water / MEOH (50 / 50, v / v)); Gradient elution: 0–3 min: 5% B; 3–15 min: 5% → 35% B; 15–18 min: 35% → 5% B; 18–25 min: 5% B; Flow rate: 0.3 mL / min; Column temperature: 80 °C; Detection wavelength: 260 nm. Mass spectrometry conditions: Ion source: Electrospray ionization (ESI); Spray voltage: 5 kV; Capillary temperature: 350 °C; Scan mode: Negative ion selected ion scanning (SIM).

[0274] The percentage of the positive strand (SS) remaining after siRNA incubation in different matrices for different times is shown in the table below.

[0275] Table 5

[0276]

[0277] The results showed that in pure water, natural miR302b, mimic10, mimic19, and mimic28 were almost unaffected after 5 hours; in mouse, rat, and human serum, natural miR302b was almost undetectable after 1 hour. The stability of all three modified mimics was increased, with the fluorinated one being the best.

[0278] Example 5: Different modifications of miR302 for the treatment of aging

[0279] In vivo delivery requires further enhancements to the mimic delivery method, such as LNP, with the addition of galnac (L96) or cholesterol (chol) to the 3' end, or polymers such as PAMAM, PEI, PLL, and PBAEs. In this embodiment, the addition of cholesterol to the 3' end is used to increase systemic distribution. The linkage between cholesterol and the nucleic acid chain is as follows... Figure 3 As shown.

[0280] One hundred and sixty 24-month-old male C57BL / 6 rats were divided into 32 groups of five rats each. They were given mimic via tail vein, 100 μl or 200 μg, once every two weeks for a total of four times.

[0281] Mouse Recording and Statistics: Mice mortality was recorded in each group, and the number of mice aged 24-28 months was counted. Mice were weighed weekly, and the weights of 24-month-old and 28-month-old mice were analyzed. Mouse skin was photographed weekly, and ImageJ was used to calculate the area of ​​alopecia areata in the mice. The area of ​​alopecia areata in 24-month-old and 28-month-old mice was statistically analyzed.

[0282] Rotating bar experiment: The mouse was placed on a rotating bar and kept at a speed of 25 rpm. The time the mouse spent on the rotating bar was recorded. After 4 days of learning, the experiment was conducted on the fifth day.

[0283] Compared to 24 months of age, approximately 60% of the mice in the control group (NC group) had died by 28 months of age. The average lifespan of C57BL / 6 mice is approximately 26-28 months, which is consistent with their median mortality rate. Average weight decreased from approximately 38g to approximately 24g, indicating weight loss due to aging. The rotarod test dwell time decreased from approximately 66s to approximately 44 seconds, showing a significant decline in balance and motor skills. Alopecia areata is a common phenomenon in aging C57BL / 6 mice, and it worsened at 28 months of age, increasing in size from approximately 1.5cm. 2 Increased to 3.1cm 2Compared to the aged mouse group at 28 months of age, over 80% of the mice in the partially administered mimic groups (mimic10, 12, 13, 14, 17, 19, 22, 23-29) survived at 28 months. The partially administered mimic groups (mimic5, 10, 12, 13, 14-16, 17-19, 22-26, 28, 29) maintained stable body weight, showing a significant difference from the control group. The partially administered mimic groups spent more time on the rotarod compared to the control group (mimic9, 10, 12, 13, 17, 19, 22-30), indicating enhanced motor and balance abilities. The area of ​​bald patches in the partially administered mimic groups was significantly smaller than that in the control group at 28 months of age (mimic10, 12, 13, 17, 19, 22-30), indicating a reversal of hair loss in aging mice. Other mimic groups showed no difference from the control group, suggesting the mice were still in a state of gradual aging. The above results further suggest that miR-302b mimic10, 12, 13, 17, 19, 22-26, 28, and 29 have the ability to reverse aging at the whole animal level.

[0284] Table 6

[0285]

[0286] Table 6 (continued)

[0287]

[0288] Example 6: miR302 mimic for the treatment of skin aging

[0289] Skin aging is a natural physiological process, and its manifestations include wrinkles, sagging, pigmentation, and dryness. Skin aging is a complex biological process involving multiple factors, including genetics, environment, and lifestyle.

[0290] Currently, strategies for alleviating skin aging include: sun protection, moisturizing, anti-oxidation, exercise, a healthy diet, regular sleep patterns, skin care (cosmetic care, beauty salon care), and medical aesthetics (laser treatment, microneedling, filler injections, etc.). While these strategies all have some effect, they often only address the symptoms, not the root cause.

[0291] A skin photoaging model was constructed: 8-week-old male Balbc mice were used, with 6 mice in each group (see table below). The mice were irradiated with UVB (310nm, 20W) at a distance of 30cm for 20 minutes at a fixed time every day for 4 weeks.

[0292] Four weeks later, the NC group mice developed numerous thick wrinkles on their backs, and the skin showed signs of keratinization. The wrinkles were scored statistically: 0 points (no thick wrinkles); 2 points (few superficial but thick wrinkles on the back); 4 points (many superficial but thick wrinkles on the back); 6 points (deep, long wrinkles on the back). The ND group had approximately 0.5 points for wrinkles.

[0293] The NC group scored 2.23 points, while some mimic groups (mimic5, 10, 12-15, 17-19, 22-30) significantly alleviated skin wrinkles compared to the NC group. These results indicate that mimic5, 10, 12-15, 17-19, and 22-30 have therapeutic effects on skin cell photoaging and pigmentation.

[0294] Table 7

[0295]

[0296] Example 7 miR302 mimic treatment for Alzheimer's disease

[0297] Alzheimer's disease (AD) is complex, and the most commonly used model is the 5xFAD model. These mice carry five mutated genes associated with Alzheimer's, including three APP gene mutations (Swedish, Florida, and London mutations) and two PSEN1 gene mutations (M146L and L286V mutations). This model encompasses almost all neuropathological features of AD, including amyloid plaques, glial cell proliferation, neurotransmission defects, synaptic loss, and neurodegenerative changes, making it an important model for studying Aβ production and toxicity. Similar to AD patients, the AD-like pathology in 5xFAD mice can be divided into three stages: an asymptomatic period around 2 months of age, during which Aβ plaques begin to appear in the cortex and hippocampus; a symptomatic period around 6 months of age, characterized by extensive amyloid pathology, neuroinflammation, significant cognitive deficits, and neurotransmission impairment; and a late-symptomatic period around 9 months of age, characterized by synaptic and neuronal loss, accompanied by severe cognitive and behavioral impairments.

[0298] Using 5xFAD mice, at 3 months of age, the drugs listed in the table (5 mice per group) were injected into the ventricle of each mouse with the drugs listed below. The drugs had cholesterol modifications at the 3' end. The dosage was 200 μg / mouse, dissolved in 50 μl of physiological saline. The drugs were administered once a month for a total of 3 months. The mice were then tested at 6 months of age.

[0299] The results showed that, compared with the NC group, the escape latency was significantly shortened in some mimic groups (mimic5, 6, 10-19, 22-26, 28-30) during the water maze test; and the blood αβ42 content was significantly reduced in some mimic groups (mimic5, 10, 12-14, 16-19, 22-30). These results suggest that mimic5, 10, 12-14, 16-19, 22-26, and 27-30 have a therapeutic effect on Alzheimer's disease.

[0300] Table 8

[0301]

[0302] Example 8: Treatment of articular cartilage damage with miR302 mimic

[0303] Articular cartilage injury and lesions are very common clinical conditions. Trauma and cartilage degeneration are the main factors contributing to articular cartilage damage. Articular cartilage is composed of chondrocytes and extracellular matrix, and is a milky-white connective tissue that covers the joint surface. It is elastic and primarily functions to cushion impact and lubricate the joint. Because articular cartilage lacks blood vessels, nerves, and lymphatic tissue, its self-repair capacity is limited, and once damaged, it is difficult to repair itself.

[0304] Experimental animals: strain: SD rat; weight: 250-280g; male.

[0305] Modeling Method: After experimental anesthesia, the leg around the knee joint was shaved, and the patient was placed supine on the operating table. The area was disinfected and draped. A 4cm incision was made on the medial side of the knee joint. The subcutaneous fascia was separated, revealing the white ligamentous tissue (patellar ligament). A small incision was gently made along the upper medial side. The patella was everted to expose the femoral-knee joint. A 4mm diameter, 3mm deep hole was drilled into the medial condyle articular surface, penetrating the subchondral bone, allowing fresh blood to seep into the joint cavity, resulting in damage to the articular cartilage throughout the procedure. The patella was repositioned, and the wound was sutured layer by layer.

[0306] At 3 months of age, the drugs listed in the table below (3 animals per group) were injected into the joint cavity with cholesterol-modified drugs at the 3' end. The dosage was 400 μg / animal, dissolved in 50 μl of physiological saline. The drugs were administered once every two weeks for a total of 4 times. Samples were collected at 5 months of age for testing.

[0307] The Modified Mankin Score was used to assess the degree of damage to articular cartilage. It mainly evaluated four aspects: cartilage structure (0-6 points), chondrocytes (0-3 points), matrix staining (0-4 points), and tidal line integrity (0-1 points). The total score was 0-14 points, with higher scores indicating more severe damage.

[0308] The proportion of Col2α1-positive cells represents the expression level of type II collagen in chondrocytes. Type II collagen is a major component of the extracellular matrix of chondrocytes and is crucial for maintaining the structure and function of cartilage. The proportion of Col2α1-positive cells reflects the activity of chondrocytes and the repair capacity of cartilage tissue, and is an important indicator for assessing cartilage damage and repair outcomes. A higher proportion of Col2α1-positive cells generally indicates better cartilage synthesis and repair functions, while a decreased proportion suggests severe cartilage degeneration or damage.

[0309] Cartilage was embedded and frozen sections were prepared. Col2α1 immunofluorescence was performed (primary antibody purchased from Abcam, AB6308; secondary antibody purchased from Santacruz) and the proportion of Col2α1 positive cells was counted.

[0310] The articular cartilage score was 12.1 in the NC group, with significant reductions in some mimic groups (mimic5, 17, 19, 22-26, 28, 29). The proportion of Col2α1 positive cells was 18.4% in the NC group, with significant reductions in some mimic groups (mimic4, 5, 7-10, 14, 16, 19, 22, 26, 28-30). These results suggest that mimics 5, 19, 22, 26, 28, and 29 have a therapeutic effect on articular cartilage damage.

[0311] Table 9

[0312]

[0313] Example 9: miR302 mimic for the treatment of diabetes and non-alcoholic fatty liver disease

[0314] A disease model was constructed using a high-fat diet combined with fructose-containing water. Specifically, 8-week-old (4-month-old) male C57BL / 6 mice were used. The normal control group was given a 4% fat maintenance diet with normal water intake; the control group was given a high-fat diet with 60% fat content, supplemented with 5% fructose in water. Modeling was successful after two months (4 months of age). The average weight of the 120 mice in the model group was 47.75 ± 2.37 g, and the average weight of the 20 mice in the normal control group was 34.15 ± 1.89 g. Regarding fasting blood glucose, the blood glucose test strips were purchased from Roche. The model group reached 12.18 ± 1.23 mM, while the normal control group reached 5.25 ± 0.94 mM, reaching the level of type 2 diabetes, and the modeling was successful.

[0315] The model group was divided into 30 groups on average, with 4 animals in each group. The animals were grouped and administered drugs according to the table below. The small nucleic acid had a galnac modification at the 3' end of the positive strand. The drugs were administered once every two weeks for a total of 4 times, with a dosage of 200 μg per animal. The experiment continued until the animals were 6 months old and then tested.

[0316] Changes in body weight are an important indicator for assessing obesity and related metabolic disorders caused by a high-sugar, high-fat diet; fasting blood glucose concentration is an important indicator for assessing glucose metabolism function; liver triglyceride (TG) content is a core indicator for assessing hepatic lipid accumulation and the development of NAFLD, as a high-sugar, high-fat diet leads to excessive lipid accumulation in the liver, thereby causing fatty liver disease; the liver fibrosis index is an important parameter for assessing liver damage and disease progression, as further development of NAFLD can lead to liver fibrosis and even cirrhosis.

[0317] Statistical analysis of mouse body weight, fasting blood glucose, liver TG content, and liver fibrosis index revealed that the NC group showed a further increase in body weight compared to 4-month-old mice, with significantly higher weights (51.2 g, 12.6 mM fasting blood glucose, and 74.2 mM liver TG content) compared to the NC group mice. The following groups showed significant reductions in body weight, liver fibrosis index, and liver fibrosis index: 1.6 μM / g (mimic5, 10, 12, 13, 15, 17, 19, 22-26, 28-30); significant decreases in blood glucose, liver TG content, and liver fibrosis index. The results above indicate that mimic5, 10, 12, 13, 19, 22, 23, 25, 26, 28, and 29 have therapeutic effects on type 2 diabetes and non-alcoholic fatty liver disease.

[0318] Table 10

[0319]

[0320] Example 10 miR302 mimic treatment for cirrhosis

[0321] Cirrhosis is a chronic liver disease characterized by fibrosis and connective tissue hyperplasia in the liver, leading to impaired liver function. Cirrhosis is an advanced liver disease that develops during chronic liver injury, characterized by the formation of new tissue that regenerates around the liver via fibrous bundles, resulting in elevated portal vein blood pressure. Many factors can contribute to cirrhosis, such as alcoholism, hepatitis C, and non-alcoholic fatty liver disease. Two stages are essential in the development of cirrhosis: inflammatory response in the liver and fibrosis.

[0322] A mouse model of liver cirrhosis induced by carbon tetrachloride (CCl4) using conventional methods:

[0323] In vivo, CCl4 is activated by detoxification enzymes such as cytochromes to form trichloromethyl radicals (CCl3*). These radicals can bind to nucleic acids, proteins, and lipids, thereby affecting cell activity. These radicals can also react with oxygen to generate a highly reactive trichloromethylperoxy radical (CCl3OO*), which can react with polyunsaturated fatty acids, especially phospholipids, thereby disrupting the permeability of cell membranes and various organelle membranes. Therefore, CCl4 is a cytotoxic substance. When CCl4 enters mouse liver cells, it activates and damages intracellular components, causing cellular inflammation. It can also induce steatosis in hepatocytes by increasing the degradation of microsomal triglyceride transfer proteins. Continued stimulation leads to the activation of hepatic stellate cells, resulting in fibrosis. Further stimulation leads to cirrhosis. Therefore, this model is a recognized classic model for simulating human cirrhosis.

[0324] Administration method: Mix 10 mL of CCl4 with 40 mL of olive oil to prepare a CCl4 solution with a final concentration of 20%. Administer CCl4 and olive oil by gavage at a volume of 1 mL / kg into the stomach of mice. Modeling was successful after one month.

[0325] The model group was divided into 30 groups, with 3 animals in each group. The animals were administered drugs according to the groupings in the table below. The small nucleic acid with a galnac modification at the 3' end of the positive strand was administered once a week for 4 weeks, at a dose of 200 μg / animal. The results were analyzed after 5 weeks. Liver fibrosis scores were calculated using paraffin-embedded chimeric trichrome staining. The liver fibrosis scoring criteria (referencing the Kleiner score) are as follows:

[0326] 0 points: No fibrosis.

[0327] 1 point: Perihepatic fibrosis or fibrosis of a single portal area.

[0328] 2 points: More than one portal area is fiberized, but it does not extend to the areas between portal areas (bridging fiberization).

[0329] 3 points: Bridging fiberization between manifolds.

[0330] 4 points: Cirrhosis.

[0331] IL-10 is an anti-inflammatory cytokine. During cirrhosis, IL-10 expression is typically upregulated as a self-protective mechanism in the inflammatory response. Abnormal upregulation of IL-10 may also reflect severe liver damage and persistent inflammation. IFNγ is a pro-inflammatory cytokine that plays an important role in liver inflammation and immune responses. Its overexpression is often associated with hepatocellular damage, persistent inflammation, and fibrosis progression. Significant upregulation of IFNγ indicates exacerbated liver inflammation and dysregulation of the immune response. Total RNA was extracted from liver tissue and detected by qPCR.

[0332] The primers are as follows, synthesized by Sangon Biotech.

[0333] IL10:

[0334] Forward PrimerCTTACTGACTGGCATGAGGATCA (SEQ ID NO: 9)

[0335] Reverse PrimerGCAGCTTCTAGGAGCATGTGG (SEQ ID NO: 10)

[0336] INF-γ

[0337] Forward PrimerGCCACGGCACAGTCATTGA (SEQ ID NO: 11)

[0338] Reverse PrimerTGCTGATGGCCTGATTGTCTT (SEQ ID NO: 12)

[0339] GAPDH

[0340] Forward PrimerAGGTCGGTGTGAACGGATTTG (SEQ ID NO: 13)

[0341] Reverse PrimerGGGGTCGTTGATGGCAACA (SEQ ID NO: 14)

[0342] Statistical analysis of liver fibrosis scores, relative IL-10 expression levels, and relative IFNγ expression levels in mice revealed that, compared to the NC group (fibrosis score 46.8, relative IL-10 expression level 12.6, relative IFNγ expression level 74.2), the partially administered mimic groups (mimic5, 12, 13, 19, 24-26, 29) showed significantly lower fibrosis scores; the partially administered mimic groups (mimic5, 9, 10, 12, 13, 17, 19, 22-26, 28, 29) showed significantly lower relative IL-10 expression levels; and the partially administered mimic groups (mimic5, 8, 10, 12, 13, 15, 18, 19, 22-26, 28-30) showed significantly lower relative IFNγ expression levels. These results indicate that mimic5, 12, 13, 19, 24-26, and 29 have a therapeutic effect on liver cirrhosis.

[0343] Table 11

[0344]

[0345] Example 11 miR302 mimic treatment for androgenetic alopecia

[0346] Androgenetic alopecia (AGA) is the most common type of hair loss. It is a chronic hair loss caused by the combined effects of genetic factors and androgens (such as dihydrotestosterone, DHT). AGA is a chronic, non-scarring, age-related progressive hair loss that begins in adolescence or late adolescence and involves the reduction of hair follicles into microfollicles. AGA is common in both men and women, especially men. In men, it manifests as a receding hairline at the forehead, temples, and scalp, with thinning and reduced hair on the crown, sometimes even revealing the scalp. In women, it manifests as progressive thinning and reduced hair on the crown and hairline, with a small percentage experiencing diffuse thinning.

[0347] Modeling method: Starting from D-2 (2 days before the experiment), administer intraperitoneal injections of 5mg / ml or 0.1ml of double-strength testosterone once daily until day 21.

[0348] Experimental grouping: The model group was divided into 30 groups on average, with 3 animals in each group. The animals were grouped and administered drugs according to the table below. The 3' end of the positive strand of the small nucleic acid was modified with chol. The drugs were administered on D0 and D5, for a total of 2 times. The dosage was 200 μg / animal, injected subcutaneously at multiple points. The results were detected on D13.

[0349] Hair was photographed on day 13 and the hair coverage on the back of mice was measured using ImageJ. The results showed that the hair coverage in the NC group was 12.1%, while the hair coverage in some mimic groups (mimic5, 6, 10, 12, 13, 19, 22-26 / 28-30) was significantly increased. The results showed that the above mimic groups had a therapeutic effect on androgenetic alopecia.

[0350] Table 12

[0351]

[0352] Example 11 miR302 mimic treatment for chronic nephritis

[0353] In recent years, chronic kidney disease (CKD) has developed into a global public health problem. The 2019 Global Burden of Disease Report showed that CKD has entered the top ten disease burden rankings for people aged 50 and over, significantly affecting their disability-adjusted life years (DALYs) and showing an increasing trend year by year. Glomerulonephritis is one of the main causes of CKD, accounting for approximately 20% of CKD cases. In younger populations, glomerulonephritis is the most common cause of end-stage renal disease. Glomerulonephritis includes subtypes such as IgA nephropathy, membranous glomerulonephritis, lupus nephritis, and focal glomerulosclerosis. Its main clinical manifestations include proteinuria, hematuria, elevated serum creatinine concentration, podocyte invagination and disappearance, edema, abnormal weight gain, and even hypertension and renal failure. Its pathogenesis is complex, involving multiple aspects such as inflammatory responses, antibody and immune cell-mediated immune responses. In addition, diseases such as obesity, hypertension, and diabetes, as well as genetic factors, can also affect the pathological process of glomerulonephritis. Approximately two-thirds of patients with primary glomerulonephritis are found to have a genetic defect. Current treatment regimens mostly use corticosteroids, calcineurin inhibitors, and renin-angiotensin system blockers, but their efficacy is unstable, relapse rates are high, adverse reactions are significant, and the number of patients developing steroid resistance is increasing year by year. Chronic nephritis (CKD) is closely related to cellular senescence. CKD is characterized by increased cellular senescence, an irreversible state of cell cycle arrest and cell division cessation. Cellular senescence characteristics are observed in all parts of the renal parenchyma in CKD patients and animal models.

[0354] Mouse model of chronic nephritis (CKD): Doxorubicin (Dox)-induced nephropathy is a classic rodent model of chronic nephritis, mimicking human chronic nephritis. The severity of tissue damage is positively correlated with mortality and weight loss, and a persistent inflammatory response is induced one week after drug administration.

[0355] Modeling method: Chronic nephritis was induced in mice using doxorubicin (Dox). Nine-week-old mice were randomly divided into three groups of eight animals each: a control group (Normal), a model group (NC), and a treatment group (miRNA302b, mimic1-30). The model and treatment groups received intraperitoneal injections of 10 mg / kg Dox according to body weight. The NC and treatment groups received subcutaneous injections of 10 mg / kg Dox (200 μl) every four days starting on day 0, in addition to the initial Dox injection. The NC group received an equal volume of physiological saline solution. Mice were continuously observed.

[0356] No deaths were observed in the blank control group. Approximately 60% of mice (5 / 8) died after Dox administration. The number of remaining mice varied in other groups (see Table 13, Endpoint Mouse Count). Serological changes: Blood tests are commonly used clinically to diagnose kidney disease. We measured the levels of creatinine (CREA) and blood urea nitrogen (BUN) in mouse serum to assess the progression of kidney disease in mice. Twenty-three days after Dox induction, the creatinine level in the blank control group was 4.5±0.8 mM, while that in the NC group was 16.8±1.9 mM, significantly higher than that in the blank control group. Serum urea nitrogen levels were 135.2±14.7 mM in the blank control group and 406.1±19.2 mM in the NC group, also significantly higher than that in the blank control group. Collagen deposition was statistically analyzed using Masson's trichrome staining after paraffin sectioning. The NC group showed a significant increase in interstitial inflammatory deposition compared to the blank control group, with some degree of glomerular hyperplasia and the onset of fibrotic deposition in the renal interstitium (appearing blue), mainly concentrated around blood vessels. The percentage of blue area was 0.9±0.5% in the blank control group and 6.2±0.8% in the NC group. These results indicate successful modeling.

[0357] Based on the above three indicators, the results showed that some mimic groups (mimic5, 12, 13, 17-19, 23-26, 28, 29) significantly reduced serum creatinine, blood urea nitrogen and collagen deposition, proving that mimic5, 12, 13, 17-19, 23-26, 28, 29 have a therapeutic effect on CKD.

[0358] Table 13

[0359]

[0360] The technical features of the above embodiments can be combined in any way. For the sake of brevity, not all possible combinations of the technical features in the above embodiments are described. However, as long as there is no contradiction in the combination of these technical features, they should be considered to be within the scope of this specification.

[0361] The embodiments described above are merely illustrative of several implementations of the present invention, and while the descriptions are relatively specific and detailed, they should not be construed as limiting the scope of the invention patent. It should be noted that those skilled in the art can make various modifications and improvements without departing from the concept of the present invention, and these all fall within the protection scope of the present invention. Therefore, the protection scope of this invention patent should be determined by the appended claims, and the specification and drawings can be used to interpret the content of the claims.

Claims

1. A double-stranded miRNA, characterized in that, It contains a chemically modified sense strand as shown in SEQ ID NO: 1, and a chemically modified antisense strand as shown in SEQ ID NO: 2; Wherein, the chemical modifications of the sense strand and the antisense strand each contain a 2'-substituted nucleotide and a modified nucleotide bond; the chemically modified nucleotide bond is located at least one or more of positions 1-3 and 20-23 of the sequences shown in SEQ ID NO: 1 and / or SEQ ID NO: 2; The modified nucleotide bond is a thiophosphate ester, and the 2'-substituted nucleotide is selected from one or more of 2'-fluorine substitution modification and 2'-O-methylation.

2. The double-stranded miRNA as described in claim 1, characterized in that, The 2'-O-methylation is located at one or more positions in positions 1-23 of the sequences shown in SEQ ID NO: 1 and / or SEQ ID NO: 2; Optionally, the 2'-O-methylation is located at one or more positions among positions 1 and 4-23 of the sequence shown in SEQ ID NO: 1 and / or SEQ ID NO: 2; further optionally, the 2'-O-methylation is located at one or more positions among positions 1, 4-12, and 14-23 of the sequence shown in SEQ ID NO: 1 and / or SEQ ID NO: 2; and even more optionally, the 2'-O-methylation is located at positions 1, 9-12, and 14-16 of the sequence shown in SEQ ID NO: 1 and / or SEQ ID NO: 2, and one or more positions among positions 20-23. Optionally, the 2'-O-methylation is located at positions 1-2 and 22-23 of the sequence shown in SEQ ID NO: 1 and / or SEQ ID NO: 2; and one or more of the spacer positions in positions 3-21.

3. The double-stranded miRNA as described in claim 1 or 2, characterized in that, The 2'-fluorine substitution modification occurs in one or more of the following groups: nucleotides containing cytosine, nucleotides containing adenine, and nucleotides containing uracil; Optionally, the 2'-fluorine substitution modification is located at least in the spacer positions of positions 3-21 of the sequences shown in SEQ ID NO: 1 and / or SEQ ID NO:

2.

4. The double-stranded miRNA according to any one of claims 1-3, characterized in that, The sense strand and / or the antisense strand further contain DNA modifications; Optionally, the DNA modification satisfies one or more of the following conditions: The DNA modification involves replacing thymine; At least one site of uracil has the DNA modification described.

5. The double-stranded miRNA as described in claim 4, characterized in that, The DNA modification satisfies one or more of the following conditions: At least one or more of the 5th, 8th, 13th, 17th and 18th positions of the sequence shown in SEQ ID NO: 1 are replaced with thymine; alternatively, all uracil in the sequence shown in SEQ ID NO: 1 are replaced with thymine. At least one or more of the 5th, 8th, 13th, 17th and 18th positions of the sequence shown in SEQ ID NO: 2 are replaced with thymine; alternatively, all uracil in the sequence shown in SEQ ID NO: 2 are replaced with thymine.

6. The double-stranded miRNA according to any one of claims 1-5, characterized in that, The sense chain and / or the antisense chain further comprises at least one terminal group; Optionally, the terminal group is a 3' terminal group; Further optionally, the terminal group is selected from the group consisting of cholesterol, bile acids, fatty acids, polyethylene glycol, antibodies, polymers, and N-acetylgalactosamine.

7. A pharmaceutical composition, characterized in that, It comprises a double-stranded miRNA as described in any one of claims 1-6, and a pharmaceutically acceptable vector.

8. An anti-aging product, characterized in that, It contains a double-stranded miRNA as described in any one of claims 1-6.

9. A liposome nanoparticle, characterized in that, It contains a double-stranded miRNA as described in any one of claims 1-6.

10. Use of the double-stranded miRNA as described in any one of claims 1-6 in the preparation of anti-aging products, medicaments for treating skin aging, medicaments for treating Alzheimer's disease, medicaments for treating articular cartilage damage, medicaments for treating diabetes, medicaments for treating non-alcoholic fatty liver disease, medicaments for treating cirrhosis, medicaments for treating androgenetic alopecia, or medicaments for treating chronic nephritis. Optionally, the method of administration of the anti-aging product or the drug is selected from the group consisting of intravenous, intramuscular, intra-arterial, intrasheath, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, tracheal, subcutaneous, subepidermal, topical application, intra-articular, subcapsular, subarachnoid, spinal, and intrasternal injection and infusion.

Citation Information

Patent Citations

  • Modified ribozymes

    US5672695A

  • Nucleoside analogs

    US6248878B1

  • Modified ribozymes

    WO1992007065A1

  • nucleozymes

    WO1993015187A1